Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Isbarn, H; Karakiewicz, PI; Vogel, S; Jeldres, C; Lughezzani, G; Briganti, A; Montorsi, F; Perrotte, P; Ahyai, SA; Budäus, L; Eichelberg, C; Heuer, R; Köllermann, J; Sauter, G; Schlomm, T; Steuber, T; Haese, A; Zacharias, M; Fisch, M; Heinzer, H; Huland, H; Chun, FK; Graefen, M.
Unilateral prostate cancer cannot be accurately predicted in low-risk patients.
Int J Radiat Oncol Biol Phys. 2010; 77(3):784-7
Doi: 10.1016/j.ijrobp.2009.05.068
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Ahyai Sascha
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Age Factors - administration & dosage
- Aged - administration & dosage
- Analysis of Variance - administration & dosage
- Biopsy, Needle - methods
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Neoplasm Invasiveness - administration & dosage
- Neoplasm Staging - administration & dosage
- Prostate - pathology, surgery
- Prostate-Specific Antigen - blood
- Prostatectomy - administration & dosage
- Prostatic Neoplasms - blood, pathology, surgery
- Find related publications in this database (Keywords)
- Prostate cancer
- Unilateral
- Prostate biopsy
- Radical prostatectomy
- Hemiablative therapy